Bulk Pharmaceutical API Sources for ranitidine bismuth citrate

Bulk Pharmaceutical API Sources for ranitidine bismuth citrate

Vendor	Vendor Homepage	Vendor Sku	API Url
AvaChem Scientific		128345-62-0
AvaChem Scientific		2622
BOC Sciences		128345-62-0
Hairui Chemical		HR124459
MolCore		MC516221

Bulk Active Pharmaceutical Ingredient (API) Sources for Ranitidine Bismuth Citrate

Last updated: August 5, 2025

---

Introduction

Ranitidine bismuth citrate, a composite pharmaceutical compound combining ranitidine—a histamine H2-receptor antagonist—and bismuth citrate, has historically been used in the treatment of Helicobacter pylori infections and related gastric conditions. Although its market presence has declined due to safety concerns surrounding ranitidine, understanding the global sources of bulk APIs remains vital for alternative manufacturing and supply chain considerations. This report provides a detailed analysis of existing API suppliers, manufacturing trends, and regional dynamics pertinent to ranitidine bismuth citrate.

---

Chemical Profile and Manufacturing Overview

Ranitidine Bismuth Citrate Composition:
The compound consists of a ranitidine molecule complexed with bismuth citrate, requiring precise synthesis protocols to ensure purity and stability. The manufacturing process involves multi-step chemical synthesis, including the production of ranitidine hydrochloride, bismuth salts, citric acid, and subsequent complexation steps.

Synthesis Complexity and Quality Standards:
Due to the complexity, GMP compliance and strict quality control are essential. APIs must meet rigorous specifications aligned with pharmacopeial standards such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.).

---

Global API Manufacturing Sources

1. China

Dominance as a Primary API Supplier
China remains the dominant manufacturer and exporter of bulk APIs, including ranitidine bismuth citrate, owing to its extensive API manufacturing infrastructure and cost advantages. Leading API producers are situated in provinces such as Shandong, Jiangsu, and Zhejiang.

Major Chinese API Producers:

• Hubei Huon Pharmaceutical Co., Ltd.
• Shandong Luyi Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.

These companies have invested in advanced synthesis capabilities and quality assurance systems, allowing compliance with international standards.

Supply Chain and Export Dynamics
Despite export restrictions and increased regulatory scrutiny following the 2020 recall of ranitidine products, some Chinese firms have continued API manufacturing for alternative compounds or non-ranitidine-based formulations. The post-2020 regulatory environment prompts suppliers to diversify or adapt their API portfolios.

2. India

Emerging as a Reliable Source
India's pharmaceutical sector has expanded its API manufacturing base, including complex compounds. While India primarily produces APIs for domestic consumption and export, its capacity for ranitidine bismuth citrate remains limited but growing.

Key Indian API Manufacturers:

• Dr. Reddy's Laboratories
• Aurobindo Pharma
• Lupin Limited

Regulatory and Quality Assurance
Indian companies adhere to strict CGMP guidelines aligned with USFDA and EMA standards, making them viable suppliers for international markets, especially where alternative suppliers are sought post-ranitidine safety concerns.

3. Europe and the United States

Limited Direct Manufacturing
European and US-based API manufacturers typically do not produce ranitidine bismuth citrate at scale due to declining demand following safety alerts. Instead, some contract manufacturing organizations (CMOs) with specialized capabilities may produce small batches for research or legacy products.

Focus on Quality and Regulatory Compliance
Manufacturers in these regions focus on high-quality synthesis, and any APIs sourced domestically tend to be for research or formulation development, not large-scale commercial supply.

---

Key Considerations in Source Selection

• Regulatory Compliance: Suppliers must demonstrate adherence to GMP standards and provide comprehensive documentation for quality, impurity profiles, and stability.
• Supply Chain Stability: Disruptions in Chinese or Indian manufacturing, such as geopolitical tensions or regulatory crackdowns, impact API availability.
• Cost and Lead Time: Chinese suppliers typically offer the lowest prices with shorter lead times, but logistical considerations and import tariffs may influence decisions.
• Reputation and Certification: ISO certifications, manufacturing licenses, and audit reports are critical indicators of supplier reliability.

---

Challenges and Future Outlook

The discontinuation of ranitidine products globally limits the demand for ranitidine bismuth citrate APIs, constraining market growth and production incentives. Going forward, the focus shifts to:

• Repurposing existing API manufacturing facilities for alternative H2-receptor antagonists or bismuth-containing compounds.
• Developing alternative sourcing strategies, including regional manufacturing hubs in Southeast Asia or Eastern Europe.
• Enhancing regulatory collaboration, ensuring compliance amidst evolving standards.

---

Conclusion

Although the market for ranitidine bismuth citrate API has significantly contracted, Chinese and Indian pharmaceutical manufacturers continue to be the primary global sources due to their established infrastructure and cost advantages. European and US-based producers are rarely involved in large-scale API manufacture for this compound, primarily providing research-grade or custom batches. Navigating regulatory landscapes and supply stability remains key for pharmaceutical companies seeking to secure bulk APIs.

---

Key Takeaways

• China dominates as the primary API source, offering the most cost-effective and scalable manufacturing options.
• India presents emerging opportunities, especially for regional or research-focused supply.
• Regulatory compliance and documentation are critical in supplier qualification.
• Market contraction due to safety concerns has impacted API availability; alternative compounds may be increasingly relevant.
• Diversification of sourcing strategies and regional manufacturing could mitigate supply chain risks.

---

FAQs

Q1. Is ranitidine bismuth citrate still commercially available?
Due to safety concerns over ranitidine's potential NDMA contamination, most global markets have ceased production and sales, reducing API demand significantly.

Q2. What are the main challenges when sourcing ranitidine bismuth citrate APIs?
Key challenges include regulatory restrictions, quality compliance requirements, supply chain disruptions, and the declining market for the compound.

Q3. Can Chinese manufacturers export ranitidine bismuth citrate API internationally?
Yes, Chinese API producers continue export activities, but ongoing regulatory scrutiny may limit certain shipments or require additional certifications.

Q4. Are there alternative suppliers outside China and India?
Limited supplies exist from niche or specialized CMOs in Europe or North America for research purposes; however, large-scale production outside Asia remains scarce.

Q5. What future trends could impact ranitidine bismuth citrate API sourcing?
Regulatory changes, patent expiries, and development of safer alternatives will influence the future landscape, potentially leading to market exit or shifting sourcing to second-generation compounds.

---

References

1. US Food and Drug Administration (FDA). "Recall of Ranitidine Drugs." 2020.
2. US Pharmacopeia (USP). Standards for Bismuth Salts and Ranitidine. 2022.
3. Global API Market Reports. "Pharmaceutical API Manufacturing Trends." 2022.
4. Company websites and industry disclosures, including those of Shandong Luyi Pharmaceutical, Zhejiang Huahai Pharmaceutical, and Dr. Reddy's Laboratories.